From Wikipedia, the free encyclopedia
Chemical compound
Emavusertib
![](https://upload.wikimedia.org/wikipedia/commons/thumb/5/54/Emavusertib.svg/220px-Emavusertib.svg.png) |
|
N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide
|
CAS Number | |
---|
PubChem
CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C24H25N7O5 |
---|
Molar mass | 491.508 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
|
InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1 Key:SJHNWSAWWOAWJH-MRXNPFEDSA-N
|
Emavusertib (CA-4948) is a drug which acts as a selective inhibitor of the enzyme
Interleukin-1 receptor-associated kinase 4 (IRAK-4) and was developed for the treatment of some forms of
cancer.
[1]
[2]
[3]
-
^ Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, et al. (December 2020).
"Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies". ACS Medicinal Chemistry Letters. 11 (12): 2374–2381.
doi:
10.1021/acsmedchemlett.0c00255.
PMC
7734642.
PMID
33335659.
-
^ Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. (May 2023).
"Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases". Clinical Cancer Research. 29 (9): 1751–1762.
doi:
10.1158/1078-0432.CCR-22-1682.
PMC
10150246.
PMID
36749885.
-
^ Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW (2023).
"IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies". Frontiers in Immunology. 14: 1239082.
doi:
10.3389/fimmu.2023.1239082.
PMC
10637517.
PMID
37954584.